This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-17 and is reviewed periodically as new material appears.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
=== Salinization/acidification of soils === Sediment from abandoned aquaculture farms can remain hypersaline, acidic and eroded. This material can remain unusable for aquaculture purposes for long periods thereafter. Various chemical treatments, such as adding lime, can aggravate the problem by modifying the physicochemical characteristics of the sediment.
Often, when British allies attempted military actions within several dozen miles or so of the sea, the Royal Navy would arrive, land troops and supplies, and aid the coalition's land forces in a concerted operation. Royal Navy ships even provided artillery support against French units when fighting strayed near enough to the coastline. The ability and quality of the land forces governed these operations. For example, when operating with inexperienced guerrilla forces in Spain, the Royal Navy sometimes failed to achieve its objectives because of the lack of manpower that the Navy's guerrilla allies had promised to supply.
=== Diagnostics === There is interest in its use in wearable technology. Sweat can be sampled and sensed non-invasively and continuously using electronic tattoos, bands, or patches. However, sweat as a diagnostic fluid presents numerous challenges as well, such as very small sample volumes and filtration (dilution) of larger-sized hydrophilic analytes. Currently the only major commercial application for sweat diagnostics is for infant cystic fibrosis testing based on sweat chloride concentrations.
=== Enrichment strategies === Previous procedures to isolate phosphorylated proteins included radioactive labeling with 32P-labeled ATP followed by SDS polyacrylamide gel electrophoresis or thin layer chromatography. These traditional methods are inefficient because it is impossible to obtain large amounts of proteins required for phosphorylation analysis. Therefore, the current and simplest methods to enrich phosphoproteins are affinity purification using phosphospecific antibodies, immobilized metal affinity chromatography (IMAC), strong cation exchange (SCX) chromatography, or titanium dioxide chromatography. Antiphosphotyrosine antibodies have been proven very successful in purification, but fewer reports have been published using antibodies against phosphoserine- or phosphothreonine-containing proteins. IMAC enrichment is based on phosphate affinity for immobilized metal chelated to the resin. SCX separates phosphorylated from non-phosphorylated peptides based on the negatively charged phosphate group. Titanium dioxide chromatography is a newer technique that requires significantly less column preparation time. Many phosphoproteomic studies use a combination of these enrichment strategies to obtain the purest sample possible.
Sources: en.wikipedia.org
== Categories defined by Kardashev == The hypothetical classification, known as the Kardashev scale, distinguishes three stages in the evolution of civilizations according to the dual criteria of access and energy consumption. The purpose of this classification is to guide the search for extraterrestrial civilizations, particularly within SETI, in which Kardashev participated, and this on the assumption that a fraction of the energy used by each type is intended for communication with other civilizations. To make this scale more understandable, Lemarchand compares the speed at which a volume of information equivalent to 100,000 average-sized books can be transmitted across the galaxy. A Type II civilization can send this data using a transmission beam that lasts for only 100 seconds. A similar amount of information can be sent across intergalactic distances of about 10 million light-years, with a transmission time of several weeks. A Type III civilization can send the same amount of data to the entire observable universe with a transmission time of 3 seconds. Kardashev's classification is based on the assumption of a growth rate of 1% per year. Kardashev believed that it would take humanity 3,200 years to reach Type II, and 5,800 years to reach Type III. However, Dr. Michio Kaku believes that humanity must increase its energy consumption by 3% per year to reach Type I in 100–200 years. These types are thus separated from each other by a growth rate of several billion.
Collagen alpha-2(IX) chain is a protein that in humans is encoded by the COL9A2 gene. This gene encodes one of the three alpha chains of type IX collagen, the major collagen component of hyaline cartilage. Type IX collagen, a heterotrimeric molecule, is usually found in tissues containing type II collagen, a fibrillar collagen. This chain is unusual in that, unlike the other two type IX alpha chains, it contains a covalently attached glycosaminoglycan side chain. Mutations in this gene are associated with multiple epiphyseal dysplasia.
Cerebras Systems Inc., headquartered in Sunnyvale, California, develops semiconductors, supercomputers, and related software to power artificial intelligence deep-learning applications such as inference engines. Products include its wafer scale engine (WSE)-3 semiconductors, its CS-3 supercomputers, and its "AI inference cloud" and "AI training cloud" APIs, which allow users to access the company's computing power without buying its hardware. The company also builds data centers using its processors and supercomputers to provide cloud computing services directly to clients. Measuring 215 mm (8.5 in) squared, the company's WSE-3 semiconductors are currently the largest AI semiconductors ever built. They take up entire silicon wafers and use wafer-scale integration and switched fabric. This reduces latency and interconnect bottlenecks compared to GPU clusters. They use static random-access memory, as opposed to dynamic random-access memory. Cerebras semiconductors and computer systems are much more powerful than those of competitors; however, they have disadvantages due to their large size, 25kW power draw, and cost of as much as $3 million per node. The company has 4 major customers: the Mohamed bin Zayed University of Artificial Intelligence (62% of 2025 revenues), G42 (24% of 2025 revenues), OpenAI (signed in 2026), and Amazon Web Services (signed in 2026). Cerebras has offices in Sunnyvale, San Diego, Toronto, and Bangalore, India. Its semiconductors are manufactured by TSMC, currently the only company that has the ability to manufacture Cerebras chips.
The Assam Legislative Assembly is the unicameral legislature of the Indian state of Assam. The Legislative Assembly comprises 126 Members of Legislative Assembly, directly elected from single-seat constituencies. Its term is five years, unless sooner dissolved. Members of the Assembly are directly elected by the people of Assam through elections held every five years, unless the Assembly is dissolved earlier. The current Assembly was elected in April–May 2026, and the next election is scheduled for 2031. The Assembly plays a key role in law-making for the state, handling crucial matters such as state budgets, development policies, and local governance. It has the authority to legislate on issues specified under the State and Concurrent Lists of the Constitution of India. The Assembly functions through various committees that handle specific issues, including the budget, public accounts, and legislative procedures. The Chief Minister, who is the leader of the majority party in the Assembly, holds executive powers and is the head of the state government.
and an honorary citizen of the cities of Frankfurt am Main and Göttingen in 1959, and of Berlin (1968). Hahn was made an Officer of the Ordre National de la Légion d'Honneur of France (1959), and was awarded the Grand Cross First Class of the Order of Merit of the Federal Republic of Germany (1959). In 1966, US President Lyndon B. Johnson and the United States Atomic Energy Commission (AEC) awarded Hahn, Lise Meitner and Fritz Strassmann the Enrico Fermi Award. The diploma for Hahn bore the words: "For pioneering research in the naturally occurring radioactivities and extensive experimental studies culminating in the discovery of fission." He received honorary doctorates from the University of Gottingen, the Technische Universität Darmstadt, the Goethe University Frankfurt in 1949, and the University of Cambridge in 1957. Objects named after Hahn include:
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.